BioMarin Pharmaceutical Inc

Add to watchlist
$81.96
Last updated:06/15/2021
BMRN: NASDAQ
BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late inf… Show more

P/E ratio
19.52x
vs. 86.96x forward

Price is 19.52x times more than EPS $4.2 which eaquals $81.96

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-117.042M
-77.211M
+34.03%
-23.848M
+69.11%
859.1M
+3702.40%
Cashflow
Sum up money going in and out company
-8.757M
20.208M
+330.76%
48.262M
+138.83%
85.365M
+76.88%
Total liabilities
All combined debts and obligations
1.824462B
1.459188B
-20.02%
1.567658B
+7.43%
1.742018B
+11.12%
Stock exposure in ETFs
ETF
Percentage of ETF
Become a premium member and see all 7 ETFs that include this stock
Company profile
CEO
Mr. Jean-Jacques Bienaime M.B.A., MBA
Market capitalization
Large (14.98B)
BMRN price history
Loading price stock history...